Compare Amphastar Pharmaceuticals Inc (AMPH) vs Medtronic PLC (MDT) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Medtronic (MDT) trades at $83.87, up 1.8% with a bullish technical signal and strong fundamental performance. The stock shows consistent earnings beats with Q1 2026 EPS of $1.55 exceeding expectations, while revenue growth accelerated to $33.54B in 2025. Analyst consensus remains strongly positive with 58% buy ratings and a $97.31 price target, representing 16% upside potential from current levels.

MDT presents an attractive investment case with solid profitability metrics, dividend aristocrat status, and accelerating revenue growth. Key risks include increasing debt levels (debt-to-asset ratio rose to 31.11% in 2025) and margin pressure from tariffs. The company's strategic acquisitions and innovation in cardiovascular and neuroscience segments support long-term growth prospects despite near-term headwinds.